Protocol of the Italian Radical Cystectomy Registry (RIC): a non-randomized, 24-month, multicenter study comparing robotic-assisted, laparoscopic, and open surgery for radical cystectomy in bladder cancer.


Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
11 Jan 2021
Historique:
received: 18 07 2020
accepted: 17 12 2020
entrez: 12 1 2021
pubmed: 13 1 2021
medline: 11 5 2021
Statut: epublish

Résumé

Bladder cancer is the ninth most common type of cancer worldwide. In the past, radical cystectomy via open surgery has been considered the gold-standard treatment for muscle invasive bladder cancer. However, in recent years there has been a progressive increase in the use of robot-assisted laparoscopic radical cystectomy. The aim of the current project is to investigate the surgical, oncological, and functional outcomes of patients with bladder cancer who undergo radical cystectomy comparing three different surgical techniques (robotic-assisted, laparoscopic, and open surgery). Pre-, peri- and post-operative factors will be examined, and participants will be followed for a period of up to 24 months to identify risks of mortality, oncological outcomes, hospital readmission, sexual performance, and continence. We describe a protocol for an observational, prospective, multicenter, cohort study to assess patients affected by bladder neoplasms undergoing radical cystectomy and urinary diversion. The Italian Radical Cystectomy Registry is an electronic registry to prospectively collect the data of patients undergoing radical cystectomy conducted with any technique (open, laparoscopic, robotic-assisted). Twenty-eight urology departments across Italy will provide data for the study, with the recruitment phase between 1st January 2017-31st October 2020. Information is collected from the patients at the moment of surgical intervention and during follow-up (3, 6, 12, and 24 months after radical cystectomy). Peri-operative variables include surgery time, type of urinary diversion, conversion to open surgery, bleeding, nerve sparing and lymphadenectomy. Follow-up data collection includes histological information (e.g., post-op staging, grading, and tumor histology), short- and long-term outcomes (e.g., mortality, post-op complications, hospital readmission, sexual potency, continence etc). The current protocol aims to contribute additional data to the field concerning the short- and long-term outcomes of three different radical cystectomy surgical techniques for patients with bladder cancer, including open, laparoscopic, and robot-assisted. This is a comparative-effectiveness trial that takes into account a complex range of factors and decision making by both physicians and patients that affect their choice of surgical technique. ClinicalTrials.gov , NCT04228198 . Registered 14th January 2020- Retrospectively registered.

Sections du résumé

BACKGROUND BACKGROUND
Bladder cancer is the ninth most common type of cancer worldwide. In the past, radical cystectomy via open surgery has been considered the gold-standard treatment for muscle invasive bladder cancer. However, in recent years there has been a progressive increase in the use of robot-assisted laparoscopic radical cystectomy. The aim of the current project is to investigate the surgical, oncological, and functional outcomes of patients with bladder cancer who undergo radical cystectomy comparing three different surgical techniques (robotic-assisted, laparoscopic, and open surgery). Pre-, peri- and post-operative factors will be examined, and participants will be followed for a period of up to 24 months to identify risks of mortality, oncological outcomes, hospital readmission, sexual performance, and continence.
METHODS METHODS
We describe a protocol for an observational, prospective, multicenter, cohort study to assess patients affected by bladder neoplasms undergoing radical cystectomy and urinary diversion. The Italian Radical Cystectomy Registry is an electronic registry to prospectively collect the data of patients undergoing radical cystectomy conducted with any technique (open, laparoscopic, robotic-assisted). Twenty-eight urology departments across Italy will provide data for the study, with the recruitment phase between 1st January 2017-31st October 2020. Information is collected from the patients at the moment of surgical intervention and during follow-up (3, 6, 12, and 24 months after radical cystectomy). Peri-operative variables include surgery time, type of urinary diversion, conversion to open surgery, bleeding, nerve sparing and lymphadenectomy. Follow-up data collection includes histological information (e.g., post-op staging, grading, and tumor histology), short- and long-term outcomes (e.g., mortality, post-op complications, hospital readmission, sexual potency, continence etc).
DISCUSSION CONCLUSIONS
The current protocol aims to contribute additional data to the field concerning the short- and long-term outcomes of three different radical cystectomy surgical techniques for patients with bladder cancer, including open, laparoscopic, and robot-assisted. This is a comparative-effectiveness trial that takes into account a complex range of factors and decision making by both physicians and patients that affect their choice of surgical technique.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov , NCT04228198 . Registered 14th January 2020- Retrospectively registered.

Identifiants

pubmed: 33430820
doi: 10.1186/s12885-020-07748-7
pii: 10.1186/s12885-020-07748-7
pmc: PMC7802145
doi:

Banques de données

ClinicalTrials.gov
['NCT04228198']

Types de publication

Clinical Trial Protocol Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

51

Références

Eur Urol. 2013 Aug;64(2):219-24
pubmed: 23395594
Eur Urol. 2017 Mar;71(3):447-461
pubmed: 27324428
J Endourol. 2016 Jul;30(7):783-91
pubmed: 27055782
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Eur Urol. 2010 Feb;57(2):196-201
pubmed: 19853987
Urol Int. 2020;104(7-8):559-566
pubmed: 32272471
Surg Technol Int. 2019 May 15;34:302-309
pubmed: 31037718
Urol Int. 2018;101(2):224-231
pubmed: 30045033
Curr Opin Urol. 2018 Jan;28(1):88-92
pubmed: 29211694
Eur Urol. 2002 Feb;41(2):105-12
pubmed: 12074395
Eur Urol. 2015 Jun;67(6):1042-1050
pubmed: 25496767
Eur Urol. 2014 Sep;66(3):569-76
pubmed: 24491306
Investig Clin Urol. 2016 Jun;57 Suppl 1:S36-43
pubmed: 27326405
BMC Urol. 2016 Sep 23;16(1):59
pubmed: 27664079
BMC Cancer. 2018 Sep 3;18(1):861
pubmed: 30176832
Eur Urol. 2017 Jan;71(1):96-108
pubmed: 27370177
Eur Urol Oncol. 2018 Oct;1(5):403-410
pubmed: 31158079
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Eur Urol. 2014 Jan;65(1):193-200
pubmed: 24018019
Cent European J Urol. 2019;72(2):113-120
pubmed: 31482017
Minerva Urol Nefrol. 2018 Apr;70(2):193-201
pubmed: 29161805
Urol Oncol. 2016 Jun;34(6):257.e1-9
pubmed: 26968561
Sci Rep. 2018 Jan 18;8(1):1129
pubmed: 29348548
Arch Ital Urol Androl. 2020 Jan 14;91(4):230-236
pubmed: 31937087
Eur Urol. 2013 Feb;63(2):234-41
pubmed: 22877502
Eur Urol Focus. 2018 Dec;4(6):937-945
pubmed: 28753879
BJU Int. 2014 Mar;113(3):458-67
pubmed: 24053793
Lancet. 2018 Jun 23;391(10139):2525-2536
pubmed: 29976469
Urol Int. 2020;104(7-8):510-522
pubmed: 32516772
Cancer. 2006 Aug 15;107(4):729-37
pubmed: 16826589
Eur Urol. 2015 Sep;68(3):399-405
pubmed: 25709026

Auteurs

Angelo Porreca (A)

Istituto Oncologico Veneto IRCCS, Padova, Italy.

Katie Palmer (K)

Department of Internal Medicine and Geriatrics, Università Cattolica del Sacro Cuore, Largo Francesco Vito, 1, 00168, 00136, Rome, Italy. katie.palmer@ki.se.

Walter Artibani (W)

Department of Urology, Policlinico Abano Terme, Abano Terme, PD, Italy.

Alessandro Antonelli (A)

Department of Urology, Azienda Ospedaliera Universitaria Integrata (A.O.U.I.), Verona, Italy.

Lorenzo Bianchi (L)

Department of Urology, University of Bologna, Bologna, Italy.

Eugenio Brunocilla (E)

Department of Urology, University of Bologna, Bologna, Italy.
Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Aldo Massimo Bocciardi (AM)

Struttura Complessa Urologia, ASST, Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Maurizio Brausi (M)

Divisione Urologia AUSL, Modena, Italy.

Gian Maria Busetto (GM)

Department of Maternal-Child and Urological Sciences, Sapienza Rome University, Policlinico Umberto I Hospital, Rome, Italy.

Marco Carini (M)

Department of Urology, Careggi Hospital, University of Florence, Florence, Italy.
Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Giuseppe Carrieri (G)

Urology and Renal Transplantation Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.

Antonio Celia (A)

Department of Urology, San Bassiano Hospital, Bassano Del Grappa, Italy.

Luca Cindolo (L)

Department of Urology, "Villa Stuart" Private Hospital, Rome, Italy.

Giovanni Cochetti (G)

Department of Urology, University of Perugia, Perugia, Italy.

Renzo Colombo (R)

Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Ettore De Berardinis (E)

Department of Maternal-Child and Urological Sciences, Sapienza Rome University, Policlinico Umberto I Hospital, Rome, Italy.

Ottavio De Cobelli (O)

IEO European Institute of Oncology, IRCCS, Milan, Italy.
Department of Hematology and Hemato-Oncology, Universty of Milan, Milan, Italy.

Fabrizio Di Maida (F)

Department of Urology, Careggi Hospital, University of Florence, Florence, Italy.

Amelio Ercolino (A)

Department of Urology, University of Bologna, Bologna, Italy.

Franco Gaboardi (F)

Department of Urology, San Raffaele Turro Hospital, Milano, Italy.

Antonio Galfano (A)

Divisione Urologia AUSL, Modena, Italy.

Andrea Gallina (A)

Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Michele Gallucci (M)

Department of Maternal-Child and Urological Sciences, Sapienza Rome University, Policlinico Umberto I Hospital, Rome, Italy.

Carlo Introini (C)

Department of Urology, E.O. Ospedali Galliera, Genova, Italy.

Ettore Mearini (E)

Department of Urology, University of Perugia, Perugia, Italy.

Andrea Minervini (A)

Department of Urology, Careggi Hospital, University of Florence, Florence, Italy.

Francesco Montorsi (F)

Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Gennaro Musi (G)

IEO European Institute of Oncology, IRCCS, Milan, Italy.

Giovannalberto Pini (G)

Department of Urology, San Raffaele Turro Hospital, Milano, Italy.

Riccardo Schiavina (R)

Department of Urology, University of Bologna, Bologna, Italy.
Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Silvia Secco (S)

Struttura Complessa Urologia, ASST, Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Sergio Serni (S)

Department of Urology, Careggi Hospital, University of Florence, Florence, Italy.
Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Claudio Simeone (C)

Department of Urology, University of Brescia, Brescia, Italy.

Giovanni Tasso (G)

Department of Urology, Careggi Hospital, University of Florence, Florence, Italy.

Daniele D'Agostino (D)

Department of Urology, Policlinico Abano Terme, Abano Terme, PD, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH